Welcome to LookChem.com Sign In|Join Free
  • or

53179-13-8

Post Buying Request

53179-13-8 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Manufacturer Supply High Quality Best Price CAS 53179-13-8 Pirfenidone API Powder
Cas No: 53179-13-8
USD $ 1500.0-1500.0 / Kilogram 1 Kilogram 100 Kilogram/Month Wuhan Vanz Pharm Inc. Contact Supplier
Pirfenidone
Cas No: 53179-13-8
No Data No Data No Data CHANGZHOU HANGYU PHARMACEUTICAL TECHNOLOGY CO., LTD Contact Supplier
Pirfenidone
Cas No: 53179-13-8
USD $ 1.0-1.0 / Gram 1 Gram 10 Metric Ton/Month LIDE PHARMACEUTICALS LIMITED Contact Supplier
Pirfenidone Manufacturer/High quality/Best price/In stock
Cas No: 53179-13-8
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Pirfenidone supplier/Factory/seller/manufacturer in China CAS NO.53179-13-8
Cas No: 53179-13-8
USD $ 1.0-3.0 / Kilogram 1 Kilogram 10 Kilogram/Day Hebei yanxi chemical co.,LTD. Contact Supplier
High purity Various Specifications Pirfenidone CAS:53179-13-8
Cas No: 53179-13-8
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Pirfenidone supplier in China
Cas No: 53179-13-8
No Data No Data No Data Simagchem Corporation Contact Supplier
Pirfenidone
Cas No: 53179-13-8
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Pirfenidone
Cas No: 53179-13-8
USD $ 1.0-1.0 / Gram 1 Gram 10 Kilogram/Month Wuhan Sunrise Technology development company limited Contact Supplier
Pirfenidone Powder USP Standard in stock manufacturer
Cas No: 53179-13-8
No Data 1 Gram 1 Metric Ton/Month Shaanxi Mingqi Chemical Co., Ltd Contact Supplier

53179-13-8 Usage

Side effects

Common adverse reactions include light sensitivity, fatigue, rash, and nausea; other adverse reactions also include upper gastrointestinal discomfort, bloating, anorexia, diarrhea, and skin itching.

Pharmacological effects

PFD is a potent inhibitor of a cytokine by regulating or inhibiting certain factors, thus inhibiting the biological activities of fibroblast cells and reducing the cell proliferation and the synthesis of collagen matrix. Meanwhile, PFD can also inhibit the secretion of inflammatory mediators, reduce lipid peroxidation, and exert its anti-inflammatory and antioxidant effects.
1. Inhibition of collagen synthesis
Fibroblast growth factor (bFGF), transforming growth factor-β (transforming growth factor-β, TGF-β), connective tissue growth factor (connective tissue growth factor, CTGF) and tissue inhibitor of metalloproteinase 1 (TIMP-1) are growth factors that related with fibrotic diseases. They can promote fibroblast proliferation and growth, increase the synthesis of collagen matrix and prevent the degradation of extracellular matrix (ECM). They are expressed to different extent during the formation of organ fibrosis. PFD can effectively reduce the expression of the proteins such as bFGF, TGF-β, CTGF and TIMP-1 in the fibroblast cells of lung and kidney and be correlated with the reduction of collagen synthesis and matrix.
The formation of I and III type collagen fibers is also closely related to the synthesis of collagen matrix. At the same time of reducing TGF-β expression, PFD can also reduce the generation α I collagen. PFD also inhibit the expression of pulmonary fibrosis I collagen. In addition, PFD also has inhibitory effect on the expression of type III collagen mRNA and can reduce the synthesis of collagen type III.
2. The anti-inflammatory effects
PFD can inhibit to the inflammatory mediators to varying degrees for exerting their anti-inflammatory effects. When the inflammatory cytokines is overexpressed inside the lung, the inflammation reaction is exacerbated, thus making alveolar wall being thickening, reducing the function of pulmonary alveoli, and ultimately causing fibrosis. PFD primarily take anti-inflammatory effects by inhibiting the expression of inflammatory mediators, reducing vascular permeability, and reducing the agglomeration of neutropenia and inflammatory cells, thus further preventing or slowing down the fibrosis of organs and tissues.
3. Anti-oxidation effect
PFD mainly exert their antioxidant effects by scavenging free radicals and inhibiting lipid peroxidation and oxidative stress mitigation.

Chemical Properties

Off-White Solid

Pharmacokinetics

After the rat intravenous injection 400 mg? kg-1 of this product, the product is cleared from the plasma according to two-compartment model with a plasma clearance rate being 0.10mL ? min-1 ? g-1 and the apparent volume of distribution being 0.6 mL ? g-1, and the half-life being 8.6min. After intravenous injection, pirfenidone is rapidly distributed in the body fluids with the drug concentration in the tissues reaching peak within 5 min with the concentration among liver, kidneys, lungs and other parts rich in blood containing relative high levels; the concentration in lower fat tissue is relative low; rat: oral administration of pirfenidone: 250~300 mg ? kg-1 ? d-1 yields a bioavailability of being 25.7%. The 24 h average plasma concentration is (1.9 ± 0.1) μg ? mL-1after 14 day of drug administration; 97 % of the metabolites are excreted from the kidney with 24 h excretion accounting for 97% of the total.

Uses

Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver

Definition

ChEBI: A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.

Clinical application

1. Idiopathic pulmonary fibrosis degeneration
Idiopathic pulmonary fibrosis (IPF) is an unexplained, poor prognosis and high-mortality chronic inflammatory interstitial lung disease. At the same time, PFD is an anti-inflammatory, anti-fibrotic agent which can be used for the treatment of IPF.
2. Liver Fibrosis
3. Renal fibrosis disease
4. Multiple Sclerosis
Multiple sclerosis (MS) is a central nervous system-related and the immune-related inflammation and demyelinating diseases. Immune factors relating to it are activation of stellate cells, glial cell, and endothelial cell and the increase of lymphocytes, while PDF have effects of inhibiting the cell activation.
5. Myocardial fibrosis
Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can all lead to myocardial fibrosis, thereby resulting in the disease progression or development. Using PDF for treatment of cardiomyopathy caused by Duchenne muscular dystrophy can inhibit myocardial fibrosis, improve the cardiac function. PFD can reduce the incidence of atrial fibrillation and myocardial remodeling through inhibiting fibrosis.
6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas.
7. Prevention of fibrosis after the organ transplant.
8. Rheumatoid arthritis.

Biological Activity

Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo . Potent scavenger of free radicals and inhibitor of lipid peroxidation.

Preparation

(1) The synthesis of the 5-methyl-2 (1H)-pyridone③
Add 1500 g (13.87 mol) of 2-amino-5-methylpyridine②, 35 L of 5% sulfuric acid to the reaction kettle and stir at room temperature for 15 min. Cool to 0~5 °C after all the solid being totally dissolved. Slowly add 1665 g of sodium nitrite (24.1 mol) into 5 L of water, stir for maintaining temperature at 3h; after the completion of the reaction, heat and reflux until no more gas is generated; use sodium carbonate to adjust pH to neutral, evaporate to dryness under reduced pressure; add 25 L of methanol to the kettle, add 30 g of activated charcoal for heating and reflux for 20min, filter, evaporate the filtrate evaporated to dryness under reduced pressure with the residue being recrystallized by ethanol to obtain pale yellow crystals③.
(2)The Synthesis of pirfenidone ①
Successively add 1000 g (9.16 mol) of 5-methyl-2 (1H)-pyridone, 2245 g (11.01 mol) of iodobenzene, 1391 g (10.08 mol) of potassium carbonate, 32.1 g (0.32 mol) of cuprous chloride and 3.5 L of dimethylsulfoxide into the 10L 3-neck flask, and stir slowly to raise the temperature to 180 °C and maintain the reaction for about 5 h. After the completion of the reaction, cool to room temperature, filter the reaction solution, wash the filter cake with 1 L of dimethyl sulfoxide; combine the filtrate and evaporate to dryness under reduced pressure; add 3 L of 20% acetic acid aqueous solution, and heat to 65 °C; stir for 30 min; stand static for layer separation; further extract the lower oil with 20% aqueous acetic acid (1L X 3) and then combine the aqueous phases. Add solid sodium hydroxide to the aqueous phase to adjust the pH to 13, cool to room temperature, separate out the precipitate; filter; wash the filter cake with water; after drying the filter cake, add 3.2L of ethyl acetate for heating reflux for about 15 min; filter it in hot condition, cool for separate the crystals; allow it to stand overnight; filter; have the filter cake dried under reduced pressure for 5h to obtain the pirfenidone①.
The synthetic route of Pirfenidone (PFD)
Figure 1 The synthetic route of Pirfenidone (PFD)
This method is a modification of the method 1, which applies the diazotization of 2-amino--5-methylpyridine, hydrolyze to obtain 5-methyl-2 (1H)-pyridone, which have reaction together with bromobenzene in 1: 1.2 (molar ratio); Using DMF as the solvent, CuBr as the catalyst, add 5% of the 1,10-phenanthrolin as the ligand, have reaction at 90°C for 2 hours to obtain the pirfenidone.
The Synthetic route of pirfenidone
Figure 2: The Synthetic route of pirfenidone

Overview

Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
InChI:InChI=1/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

53179-13-8 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
Sigma (P2116)  Pirfenidone  ≥97% (HPLC) 53179-13-8 P2116-50MG 4,917.51CNY Detail
Sigma (P2116)  Pirfenidone  ≥97% (HPLC) 53179-13-8 P2116-10MG 1,105.65CNY Detail
Sigma-Aldrich (Y0001769)  Pirfenidone  European Pharmacopoeia (EP) Reference Standard 53179-13-8 Y0001769 1,880.19CNY Detail
TCI America (P1871)  Pirfenidone  >98.0%(GC) 53179-13-8 1g 1,200.00CNY Detail
TCI America (P1871)  Pirfenidone  >98.0%(GC) 53179-13-8 100mg 280.00CNY Detail

53179-13-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name pirfenidone

1.2 Other means of identification

Product number -
Other names Pirfenidone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:53179-13-8 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields